Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.

Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.

OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Fo-Ti is discussed as a potential treatment for hair loss, but its effectiveness is questioned. Users express skepticism and caution about its use.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.

A dermatologist prescribed Betnovate scalp, a corticosteroid, for a 21-year-old male's hair loss due to DHT. The individual is considering using Nizoral shampoo, topical finasteride, a derma roller, and minoxidil, but is unsure about the effectiveness of two other products suggested by the dermatologist.